非酒精性脂肪性肝病的展望：当前及未来治疗方法概述
Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies.
作者信息
Vizuete John, Camero Alfredo, Malakouti Mazyar, Garapati Karthik, Gutierrez Julio
机构信息
Department of Medicine, Division of Gastroenterology, University of Texas Health Science Center San Antonio, San Antonio, TX, USA.
The Texas Liver Institute, San Antonio, TX, USA.
出版信息
J Clin Transl Hepatol. 2017 Mar 28;5(1):67-75. doi: 10.14218/JCTH.2016.00061. Epub 2017 Mar 20.
Abstract
Nonalcoholic fatty liver disease (NAFLD) represents a major public health epidemic. Pharmacologic therapies for this condition are scarce, but multiple agents with novel mechanisms of action are in development. Here we review the pathophysiology and natural history of NALFD, diagnostic testing and data for currently available treatment strategies. We then turn our attention to promising developmental drugs and their respective trials. As the prevalence of fatty liver disease increases, clinicians will have more tools at hand for management of this condition. We conclude the horizon is bright for patients and doctors who deal with NAFLD.
摘要
非酒精性脂肪性肝病（NAFLD）是一种主要的公共卫生流行病。针对这种疾病的药物治疗方法稀缺，但多种具有新型作用机制的药物正在研发中。在此，我们综述NAFLD的病理生理学和自然史、诊断检测以及当前可用治疗策略的数据。然后，我们将注意力转向有前景的正在研发的药物及其各自的试验。随着脂肪性肝病患病率的增加，临床医生在管理这种疾病时将有更多手段。我们得出结论，对于治疗NAFLD的患者和医生来说，前景是光明的。
相似文献
1
Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies.非酒精性脂肪性肝病的展望：当前及未来治疗方法概述
J Clin Transl Hepatol. 2017 Mar 28;5(1):67-75. doi: 10.14218/JCTH.2016.00061. Epub 2017 Mar 20.
2
New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis.非酒精性脂肪性肝病的新治疗策略：关注非酒精性脂肪性肝炎的有前途药物。
Pharmacol Rep. 2020 Feb;72(1):1-12. doi: 10.1007/s43440-019-00020-1. Epub 2020 Jan 8.
3
Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.与健康正常体重个体相比，不同程度非酒精性脂肪性肝病患者的肝转录组特征。
Am J Physiol Gastrointest Liver Physiol. 2019 Apr 1;316(4):G462-G472. doi: 10.1152/ajpgi.00358.2018. Epub 2019 Jan 17.
4
Obesity and nonalcoholic fatty liver disease: current perspectives.肥胖与非酒精性脂肪性肝病：当前观点
Diabetes Metab Syndr Obes. 2018 Sep 25;11:533-542. doi: 10.2147/DMSO.S146339. eCollection 2018.
5
Natural History of Simple Steatosis or Nonalcoholic Fatty Liver.单纯性脂肪变性或非酒精性脂肪肝的自然史
J Clin Exp Hepatol. 2020 May-Jun;10(3):255-262. doi: 10.1016/j.jceh.2019.09.005. Epub 2019 Sep 20.
6
Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.生物信息学分析揭示了与非酒精性脂肪性肝病和非酒精性脂肪性肝炎相关的新核心基因。
Gene. 2020 Jun 5;742:144549. doi: 10.1016/j.gene.2020.144549. Epub 2020 Mar 14.
7
Natural History of Non-Alcoholic Fatty Liver Disease: A Study With Paired Liver Biopsies.非酒精性脂肪性肝病的自然史：一项配对肝活检研究
J Clin Exp Hepatol. 2020 May-Jun;10(3):245-254. doi: 10.1016/j.jceh.2019.07.002. Epub 2019 Jul 15.
8
Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease.新兴和成熟的非酒精性脂肪性肝病治疗方法。
Clin Ther. 2021 Sep;43(9):1476-1504. doi: 10.1016/j.clinthera.2021.07.013. Epub 2021 Aug 24.
9
LC-MS-based lipidomic analysis in distinguishing patients with nonalcoholic steatohepatitis from nonalcoholic fatty liver.基于 LC-MS 的脂质组学分析在鉴别非酒精性脂肪性肝炎与非酒精性脂肪肝患者中的应用。
Hepatobiliary Pancreat Dis Int. 2021 Oct;20(5):452-459. doi: 10.1016/j.hbpd.2021.05.008. Epub 2021 Jun 25.
10
Diagnostic and Treatment Implications of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.非酒精性脂肪性肝病和非酒精性脂肪性肝炎的诊断与治疗意义
Gastroenterol Hepatol (N Y). 2019 Feb;15(2):83-89.
引用本文的文献
1
Berberine in Non-Alcoholic Fatty Liver Disease-A Review.小檗碱在非酒精性脂肪性肝病中的作用-综述。
Nutrients. 2022 Aug 23;14(17):3459. doi: 10.3390/nu14173459.
2
Impact of the Co-Administration of N-3 Fatty Acids and Olive Oil Components in Preclinical Nonalcoholic Fatty Liver Disease Models: A Mechanistic View.ω-3 脂肪酸与橄榄油成分联合应用于非酒精性脂肪性肝病模型的临床前研究：一种机制观点。
Nutrients. 2020 Feb 15;12(2):499. doi: 10.3390/nu12020499.
3
Hepatic exposure of metformin in patients with non-alcoholic fatty liver disease.非酒精性脂肪性肝病患者中二甲双胍的肝脏暴露情况。
Br J Clin Pharmacol. 2019 Aug;85(8):1761-1770. doi: 10.1111/bcp.13962. Epub 2019 Jun 18.
4
Potential Nexus of Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Insulin Resistance Between Hepatic and Peripheral Tissues.非酒精性脂肪性肝病与2型糖尿病之间的潜在联系：肝脏与外周组织之间的胰岛素抵抗
Front Pharmacol. 2019 Jan 14;9:1566. doi: 10.3389/fphar.2018.01566. eCollection 2018.
5
Relationship between Experimental Diet in Rats and Nonalcoholic Hepatic Disease: Review of Literature.大鼠实验性饮食与非酒精性肝病的关系：文献综述
Int J Hepatol. 2018 Oct 31;2018:9023027. doi: 10.1155/2018/9023027. eCollection 2018.
6
A Case of Concomitant Obstructive Sleep Apnea and Non-Alcoholic Steatohepatitis Treated With CPAP Therapy.1例阻塞性睡眠呼吸暂停合并非酒精性脂肪性肝炎患者接受持续气道正压通气（CPAP）治疗的病例
Gastroenterology Res. 2018 Jun;11(3):252-259. doi: 10.14740/gr1033w. Epub 2018 May 31.
7
Mediterranean Diet and Multi-Ingredient-Based Interventions for the Management of Non-Alcoholic Fatty Liver Disease.地中海饮食和多成分干预措施在非酒精性脂肪性肝病管理中的应用。
Nutrients. 2017 Sep 22;9(10):1052. doi: 10.3390/nu9101052.
8
Dietary Composition Independent of Weight Loss in the Management of Non-Alcoholic Fatty Liver Disease.饮食组成与非酒精性脂肪性肝病管理中的体重减轻无关。
Nutrients. 2017 Jul 26;9(8):800. doi: 10.3390/nu9080800.
9
The challenges and promise of targeting the Liver X Receptors for treatment of inflammatory disease.针对肝 X 受体治疗炎症性疾病的挑战与前景。
Pharmacol Ther. 2018 Jan;181:1-12. doi: 10.1016/j.pharmthera.2017.07.010. Epub 2017 Jul 16.
本文引用的文献
1
Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal.赖氨酸氧化酶样蛋白2（LOXL2）的选择性靶向作用可抑制肝纤维化进展并加速其逆转。
Gut. 2017 Sep;66(9):1697-1708. doi: 10.1136/gutjnl-2016-312473. Epub 2017 Jan 10.
2
Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis.随机临床研究：GR-MD-02，一种半乳糖凝集素-3 抑制剂，与安慰剂在非酒精性脂肪性肝炎伴晚期纤维化患者中的比较。
Aliment Pharmacol Ther. 2016 Dec;44(11-12):1183-1198. doi: 10.1111/apt.13816. Epub 2016 Oct 24.
3
Effect of Liraglutide Therapy on Liver Fat Content in Patients With Inadequately Controlled Type 2 Diabetes: The Lira-NAFLD Study.利拉鲁肽治疗对2型糖尿病控制不佳患者肝脏脂肪含量的影响：利拉鲁肽-非酒精性脂肪性肝病研究
J Clin Endocrinol Metab. 2017 Feb 1;102(2):407-415. doi: 10.1210/jc.2016-2775.
4
Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design.塞尼西维罗克治疗伴有肝纤维化的成年非酒精性脂肪性肝炎受试者的疗效和安全性研究：CENTAUR 2b期研究设计
Contemp Clin Trials. 2016 Mar;47:356-65. doi: 10.1016/j.cct.2016.02.012. Epub 2016 Mar 2.
5
Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.依洛前列素，一种过氧化物酶体增殖物激活受体-α和-δ激动剂，可在不加重肝纤维化的情况下诱导非酒精性脂肪性肝炎消退。
Gastroenterology. 2016 May;150(5):1147-1159.e5. doi: 10.1053/j.gastro.2016.01.038. Epub 2016 Feb 11.
6
Prevalence of biopsy-proven non-alcoholic fatty liver disease in severely obese subjects without metabolic syndrome.无代谢综合征的严重肥胖受试者中经活检证实的非酒精性脂肪性肝病患病率
Clin Obes. 2016 Apr;6(2):117-23. doi: 10.1111/cob.12132. Epub 2016 Feb 8.
7
A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus.一项为期48周的随机2b期研究，评估塞尼西维罗与依非韦伦在初治的感染C-C趋化因子受体5型嗜性病毒的成人HIV感染者中的疗效。
AIDS. 2016 Mar 27;30(6):869-78. doi: 10.1097/QAD.0000000000000988.
8
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.利拉鲁肽治疗非酒精性脂肪性肝炎（LEAN）患者的安全性和有效性：一项多中心、双盲、随机、安慰剂对照的 2 期研究。
Lancet. 2016 Feb 13;387(10019):679-690. doi: 10.1016/S0140-6736(15)00803-X. Epub 2015 Nov 20.
9
Systematic review: Preventive and therapeutic applications of metformin in liver disease.系统评价：二甲双胍在肝脏疾病中的预防和治疗应用
World J Hepatol. 2015 Jun 28;7(12):1652-9. doi: 10.4254/wjh.v7.i12.1652.
10
Cost-utility analysis of nonalcoholic steatohepatitis screening.非酒精性脂肪性肝炎筛查的成本效用分析
Eur Radiol. 2015 Nov;25(11):3282-94. doi: 10.1007/s00330-015-3731-2. Epub 2015 May 21.
Zotero 插件